David Wilkins, PA
Medical · Muskegon, MINPI 1740230200
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Amgen at 57.6% of the total. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,269 payments — averaging $32.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$24K
- AbbVie$3K
- Supernus Pharmaceuticals, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$983
- Novo Nordisk$973
- Lilly USA, LLC$937
- plus $10K from 54 others
What the payments were for
- Speaking & faculty fees$20,68850%
- Travel & lodging$8772%
- Food & beverage$19,26347%
- Education$2301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,058 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 20 | $252,513 |
| TrulicityDulaglutide | 136 | $146,674 |
| JardianceEmpagliflozin | 175 | $138,221 |
| GlyxambiEmpagliflozin/Linagliptin | 188 | $113,622 |
| MounjaroTirzepatide | 97 | $100,289 |
| EliquisApixaban | 135 | $93,280 |
| Humira PenAdalimumab | 13 | $91,624 |
| CreonLipase/Protease/Amylase | 21 | $79,810 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $74,623 |
| KerendiaFinerenone | 87 | $72,180 |
| OzempicSemaglutide | 66 | $64,351 |
| LinzessLinaclotide | 112 | $64,066 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 87 | $63,707 |
| ZenpepLipase/Protease/Amylase | 16 | $56,089 |
| XareltoRivaroxaban | 87 | $52,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat, Trijardy Xr | $918 | $274,722408 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $937 | $246,963233 claims |
| AbbVieCreon, Linzess, Vraylar | $3,088 | $183,052161 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $764 | $98,664140 claims |
| PfizerEliquis | $775 | $93,280135 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $726 | $85,743119 claims |
| BayerKerendia | $232 | $72,18087 claims |
| Novo NordiskOzempic | $973 | $64,35166 claims |
| Johnson & JohnsonXarelto | $330 | $52,99487 claims |
| AmgenOtezla | $23,640 | $52,04711 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $483 | $42,37931 claims |
| Alkermes, Inc.Lybalvi, Vivitrol | $671 | $37,58323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.
Other medical in Muskegon
- Heidi JacksonMuskegon$11K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.